Literature DB >> 10649244

Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?

J W Marsh1, I Dvorchik, C A Bonham, S Iwatsuki.   

Abstract

BACKGROUND: The pathologic TNM (pTNM) staging system was designed to aid in determining the prognosis of cancer patients and in planning and evaluating their treatment. The current pTNM classification system was not found to be predictive for patients undergoing orthotopic liver transplantation (OLTx) in the presence of hepatocellular carcinoma (HCC). Therefore, the authors examined the current system to determine whether improvements would allow the development of a more predictive system.
METHODS: Three hundred seven patients with HCC underwent OLTx between 1981 and 1997. Risk factors for recurrence were identified using the Kaplan-Meier method with the log rank test. The Cox proportional hazards model was used to identify factors independently predictive of recurrence which were then used to create a new staging system.
RESULTS: There was neither a direct correlation between the current pTNM system and tumor free survival nor homogeneity in outcomes for patients within certain current pTNM categories. Depth of vascular invasion, lobar distribution, lymph node status, and largest tumor size were found to be independent predictors of tumor free survival; tumor number was not found to be significant in multivariate analysis. A new staging system is proposed, which takes into account the results of the multivariate analysis in which tumor free survival correlates directly with stage.
CONCLUSIONS: The proposed staging system is superior to the current pTNM staging system in predicting tumor free survival following OLTx with HCC. Further studies will determine the appropriateness of this system for staging HCC after subtotal hepatic resection. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10649244     DOI: 10.1002/(sici)1097-0142(20000201)88:3<538::aid-cncr7>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  53 in total

Review 1.  Moving toward an understanding of the metastatic process in hepatocellular carcinoma.

Authors:  W M Korn
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

Review 2.  Hepatocellular carcinoma: epidemic and treatment.

Authors:  Jill Allen; Alan Venook
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

3.  Obesity and microvascular invasion in hepatocellular carcinoma.

Authors:  Abby B Siegel; Shuang Wang; Judith S Jacobson; Dawn L Hershman; Emerson A Lim; Jeanette Yu; Lauren Ferrante; Kalpana M Devaraj; Helen Remotti; Shannon Scrudato; Karim Halazun; Jean Emond; Lorna Dove; Robert S Brown; Alfred I Neugut
Journal:  Cancer Invest       Date:  2010-12       Impact factor: 2.176

4.  Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients.

Authors:  R Tateishi; H Yoshida; S Shiina; H Imamura; K Hasegawa; T Teratani; S Obi; S Sato; Y Koike; T Fujishima; M Makuuchi; M Omata
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

5.  Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma.

Authors:  Young Je Park; Do Hoon Lim; Seung Woon Paik; Kwang Cheol Koh; Joon Hyoek Lee; Moon Seok Choi; Byung Chul Yoo; Hee Rim Nam; Dong Ryul Oh; Won Park; Yong Chan Ahn; Seung Jae Huh
Journal:  J Gastroenterol       Date:  2006-12-08       Impact factor: 7.527

6.  Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Kathy Han; George N Tzimas; Jeffrey S Barkun; Peter Metrakos; Jean L Tchervenkov; Nir Hilzenrat; Phil Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

7.  Liver transplantation for hepatocellular carcinoma.

Authors:  A W Hemming; M S Cattral; A I Reed; W J Van Der Werf; P D Greig; R J Howard
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

8.  Outcome comparisons among the Hangzhou, Chengdu, and UCSF criteria for hepatocellular carcinoma liver transplantation after successful downstaging therapies.

Authors:  Jianyong Lei; Lunan Yan
Journal:  J Gastrointest Surg       Date:  2013-01-17       Impact factor: 3.452

9.  The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.

Authors:  Xiao Xu; Qing-Hong Ke; Zhe-Xin Shao; Jian Wu; Jun Chen; Lin Zhou; Shu-Sen Zheng
Journal:  Dig Dis Sci       Date:  2008-06-18       Impact factor: 3.199

10.  Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation?

Authors:  Richard S Young; Mohammed Aldiwani; Abdul R Hakeem; Amit Nair; Ashley Guthrie; Judy Wyatt; Darren Treanor; Gareth Morris-Stiff; Rebecca L Jones; K Rajendra Prasad
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.